Create a narrative

Alector Community

NasdaqGS:ALEC Community

1 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Key Takeaways Alector's ABC platform and late-stage trials, like those for latozinemab, could significantly boost revenue if successful, addressing unmet medical needs. Strong cash reserves support pipeline progression, potentially stabilizing R&D costs and enhancing net margins as programs near commercialization.

US$4.76

FV

63.0% undervalued

49.52%

Revenue growth p.a.

0

0

2

5 days ago